Correlation between the Appropriateness of Anti-Tuberculosis Drug Therapy and the Recovery of Pulmonary Tuberculosis Patients
DOI:
https://doi.org/10.53089/medula.v13i4.769Keywords:
Pulmonary tuberculosis, Appropriateness Therapy, Anti-Tuberculosis DrugAbstract
Mycobacterium tuberculosis is an acid-fast bacillus that can cause tuberculosis infection. This disease often attacks humans, especially the lungs, which is also called pulmonary TB. However, these bacteria can also attack organs other than the lungs, which is also called extrapulmonary TB. It is estimated that a third of the world's population has been infected with this bacterium. According to the World Health Organization (WHO) in 2019, tuberculosis is one of the infectious diseases that causes the highest death in the world. The accuracy of the use of anti-tuberculosis drugs in the therapy of tuberculosis patients themselves is assessed based on the accuracy of the indication, the accuracy of the patient, the accuracy of the drug, and the accuracy of the dosage. The results expected in pulmonary TB therapy can be marked by examining the results of bacteriological examination, namely by examining AFB sputum which is carried out at the end of therapy for pulmonary TB patients and/or by the decision of the doctor in charge. The results of this negative AFB bacteriological examination indicate that the patient has recovered from pulmonary TB. The accuracy of the indication, the accuracy of the patient, the accuracy of the drug, and the accuracy of the dosage of anti-tuberculosis drugs and the patient complying with the complete treatment regimen, both the dosage and the duration of treatment are factors that can determine the success of patient treatment.
Keywords: Pulmonary tuberculosis, Appropriateness Therapy, Anti-Tuberculosis Drug
References
Panggayuh PL, Winarno ME, Tama TD. Faktor yang Berhubungan dengan Keberhasilan Pengobatan Tuberkulosis Paru di Rumah Sakit Umum Karsa Husada Batu. Sport and Science Health. 2019;1(1): 28-38.
Nurhakim AD, Mashoedojo , Harfiani E. Faktor apa yang mempengaruhi rendahnya tingkat pengobatan tuberkulosis di Lagoa Jakarta?. Jurnal Ilmiah Kesehatan Masyarakat. 2020;12(3): 110-117.
Fraga ADSS, Oktavia N, Mulia RA. Evaluasi penggunaan obat anti tuberkulosis pasien baru tuberkulosis paru di Puskesmas Oebobo Kupang Tahun 2020. Jurnal Farmagazine. 2021; 8(1):17-24.
World health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization. 2022
Anuku T, Pareta D, Kanter J, Untu S. Evaluasi rasionalitas penggunaan obat anti tuberkulosis pada pasien tuberkulosis paru di Puskesmas IBU Kabupaten Halmahera Barat. Biofarmasetikal Tropis. 2020;3(1): 101-107.
Hidayat AR, Nurhayati I. Perawatan pasien dengan tuberkulosis paru di Rumah Sakit Panti Nugroho, Sleman: studi kasus. Jurnal Kesehatan Tujuh Belas. 2019;1(1): 7-13.
Naftali AV, Farizi GRA, Ovikariani. Studi pola penggunaan obat anti tuberkulosis pada pasien tuberkulosis paru. Jurnal Surya Medika. 2022;8(1): 161-167.
Dewanti GP, Masfuri. Efektivitas pelaporan mandiri berbasis digital terhadap kepatuhan penyelesaian pengobatan tuberkulosis: literature review. Jurnal of Nursing Care. 2023;6(1): 77-86.
Amin Z, Bahar A. Tuberkulosis paru. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. Buku ajar ilmu penyakit dalam jilid I. Edisi ke-6. Jakarta: Pusat Penerbitan Dapertemen Ilmu Penyakit Dalam FK UI. 2014: 863-873
Surani I, Nofita, Ulfa AM. Evaluasi rasionalitas penggunaan obat antituberkulosis pada pasien tuberkulosis paru di Puskesmas Sriwijaya Kabupaten Lampung Tengah. Jurnal Ilmu Kedokteran dan Kesehatan. 2022;9(4): 1187-1177.
Sari KEP, Rizkifani S, Iswahyudi. Evaluasi penggunaan obat anti tuberkulosis pada pasien baru tuberkulosis paru dewasa rawat jalan di RS. TK. II Kartika Husada Kubu Raya Tahun 2020. Jurnal Mahasiswa Farmasi Fakulas Kedokteran UNTAN. 2021;5(1): 1-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
